

The Neurology Center of Southern California
6010 Hidden Valley Rd. Suite 200, Carlsbad, CA 92011
Ph. 760-631-3000 Fax 760-631-3016
www.neurocenter.com



Brenton A. Wright, MD

EDUCATION

University of Virginia , Charlottesville, VA B.A. Biology with Highest Distinction 5/16/04	08/2000 – 05/2000
University of Louisville School of Medicine , Louisville, KY M.D. May 10, 2008	08/2004 – 05/2008
Columbia University College of Physicians and Surgeons , New York, NY Internship in Internal Medicine	07/2008 – 06/2009
Columbia University College of Physicians and Surgeons , New York, NY Residency in Neurology	07/2009 – 06/2012
Neurological Institute of New York/CUMC , New York, NY Clinical Fellowship, Movement Disorders	07/2012 – 06/2014

LICENSURE & CERTIFICATION

• American Board of Psychiatry and Neurology, Neurology	09/2021 – Present
• California Medical License Number # C152156	10/2017 – Present
• State of New York #60254207	07/2009 – 09/2014
• State of Missouri # MD2014020145	06/2014 – 01/2018

PROFESSIONAL SOCIETIES

- Parkinson Study Group
- Huntington Study Group
- International Parkinson and Movement Disorders Society
- American Neurological Association
- American Academy of Neurology
- American Medical Association

PROFESSIONAL EXPERIENCE

The Neurology Center of Southern California , Carlsbad, CA Neuro-hospitalist	05/2023 - Present
Parkinson's Association of San Diego <i>Medical Advisory Director</i>	11/2022 - Present
VA San Diego Healthcare System Center Staff Physician	05/2018 – 04/2023
University of California San Diego , San Diego, CA Assistant Professor of Clinical Neurosciences Associate Professor of Clinical Neurosciences	12/2017 – 11/2022 11/2022 – 04/2023
Fellowship Director, Movement Disorders	03/2019 – 02/2023
Washington University School of Medicine , St. Louis, MO Assistant Professor of Neurology	09/2014 – 11/2017

HOSPITAL AFFILIATIONS

• Tri-City Medical Center , Oceanside, California	Pending Privileges
• Palomar Medical Center , Escondido, California	Pending Privileges
• Palomar Medical Center , Poway, California	Pending Privileges
• Scripps Memorial Hospital , Encinitas, California	04/2023 - Present
• Scripps Mercy Hospital , Chula Vista, California	Pending Privileges

HONORS & AWARDS

Eagle Scout	1997
National Merit Finalist	1999
University of Virginia Echols Scholar	2000-2004
University of Virginia Intermediate Honors	2002
Phi Beta Kappa, Beta Chapter of Virginia	2003
University of Louisville School of Medicine Dean's Merit Scholarship	2004-2008
AAN Medical Student Prize for Excellence in Neurology	2008
Travel Grant, International Congress of Parkinson's Disease & Movement Disorders	2014

GAP EXPLANATION

Fellowship in Movement Disorders was completed at the Neurological Institute of NY/Columbia College of Physicians and Surgeons on 6/30/2014. My appointment as Assistant Professor of Neurology at Washington University School of Medicine began on 9/15/2014.

During the 10-week gap, I moved from New York City to St. Louis, spent time with family, travelled, worked to get settled in St. Louis, and completed orientation activities for Washington University and Barnes-Jewish Hospital.

RESEARCH SUPPORT

NCT01850381 PI: Fahn, S April 2013 – June 2014

Genervon Biopharmaceuticals, LLC

GM602 (aka GM608) in a Phase IIA pilot double-blinded, randomized, placebo-controlled trial in mild to moderate Parkinson's Disease (PD)

Role: Sub-Investigator

NCT01705327 PI: Alcalay, R June 2013 – June 2014

Michael J. Fox Foundation/NINDS

Fox Investigation for new discovery of biomarkers (BioFind)

Role: Sub-Investigator

NCT00660673 PI: Waters, C July 2013 – June 2014

AbbVie Pharmaceuticals

Open-label continuation treatment study with carbidopa-levodopa intestinal gel in subjects with advanced Parkinson's Disease and severe motor fluctuations who have exhibited a persistent and positive effect to treatment in previous studies.

Role: Sub-Investigator

NCT02215616 PI: Racette, B January 2015 – November 2017

Teva Branded Pharmaceutical Products, R&D Inc.

A multicenter, multinational, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of Laquinimod (0.5, 1.0 and 1.5 mg/Day) as treatment in patients with Huntington's disease.

Role: Sub-Investigator

NCT02242487 PI: Criswell, S February 2015 – November 2017

Accorda Therapeutics

A Phase 2b, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of inhaled CVT 301 (levodopa inhalation powder) in Parkinson's disease patients with motor response fluctuations (OFF phenomena)

Role: Sub-Investigator

NCT02453386 PI: Racette, B June 2015 - November 2017

Biotie Therapies Inc.

A phase 3, multicenter, randomized, double-blind, placebo-controlled study with an open-label phase to determine the efficacy and safety of tozadenant as adjunctive therapy in levodopa-treated patients with Parkinson's disease experiencing end of dose "wearing-off" (TOZ-PD)

Role: Sub-Investigator

NCT02481674 PI: Racette, B July 2015 - November 2017

Vaccinex Inc.

A phase 2, multi-center, randomized, double-blind, placebo-controlled study in subjects with late prodromal and early manifest Huntington disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503

Role: Sub-Investigator

NCT02611713 PI: Kotzbauer, Paul October 2015 - November 2017

Brenton A. Wright, M.D.

AbbVie Pharmaceuticals

Observational study evaluating long term effectiveness of Duodopa/Duopa in Parkinson disease (DUOGLOBE)

Role: Sub-Investigator

NCT02507284 PI: Wright, B December 2015 - November 2017

Azevan Pharmaceuticals/NINDS/NeuroNEXT Network

Tolerability, safety, and activity of SRX246 in irritable subjects with Huntington's disease

Role: Primary Investigator

NCT02985879 PI: Litvan, I January 2018 – June 2020

AbbVie Pharmaceuticals

A randomized, double-blind, placebo-controlled multiple dose study to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy

Role: Sub-Investigator

NCT03040713 PI: Litvan, I January 2018 – April 2019

Avid Radiopharmaceuticals

18F-AV-1451 PET in subjects with Frontotemporal Dementia

Role: Sub-Investigator

NCT03068468 PI: Litvan, I January 2018 – July 2020

Biogen

A randomized, double-blind, placebo-controlled, parallel-Group Study to evaluate the efficacy and safety of intravenously administered BIIB092 in participants with Progressive Supranuclear Palsy (PASSPORT)

Role: Sub-Investigator

NCT02658916 PI: Litvan, I January 2018 – September 2020

Biogen

A multicenter, open-label, long-term treatment study of intravenously administered BIIB092 in participants with Progressive Supranuclear Palsy who participated in CN002003.

Role: Sub-Investigator

NCT03100149 PI: Litvan, I January 2018 – April 2023

Roche

A randomized, double-blind, placebo-controlled, 52-week phase II study to evaluate the efficacy of intravenous RO7046015 (PRX002) in participants with early Parkinson's disease with a 52-week blinded extension (PASADENA)

Role: Sub-Investigator

NCT02642393 PI: Litvan, I February 2018 – November 2019

Michael A. Schwarzschild/Parkinson Study Group/NINDS/Michael J. Fox Foundation

Study of Urate elevation in Parkinson's disease, Phase 3 (SURE-PD3)

Role: Sub-Investigator

NCT01804452 PI: Litvan, I April 2018 – April 2023

NIH, National Institute on Aging

4 Repeat Tauopathy Neuroimaging Initiative (4RTNI)

Role: Sub-Investigator

NCT02481674 PI: Corey-Bloom, J October 2018 – January 2021

Vaccinex Inc.

A phase 2, multi-center, randomized, double-blind, placebo-controlled study in subjects with late prodromal and early manifest Huntington disease (HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503

Role: Sub-Investigator

NCT03761849 PI: Corey-Bloom, J January 2019 – March 2022

Hoffmann La-Roche

A multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of intrathecally administered RO7234292.(RG6042) in patients with manifest Huntington's disease

Role: Sub-Investigator

Brenton A. Wright, M.D.

NCT03225846 PI: Corey-Bloom, J January 2019 – May 2021
 Wave Biosciences Ltd.
A multicenter, randomized, double-blind, placebo-controlled, phase 1b/2a study of WVE-120102 administered intrathecally in patients with Huntington's disease (PRECISION-HD2)
 Role: Sub-Investigator

NCT02623699 PI: Ravits, J July 2019 – July 2021
 Biogen/Ionis
An efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics study of BIIB067 administered intrathecally to adults with ALS and confirmed SOD1 mutation.
 Role: Sub-Investigator

NCT03070119 PI: Ravits, J July 2019 – April 2023
 Biogen
Long term evaluation of BIIB067 administered intrathecally to adults with ALS and confirmed SOD1 mutation.
 Role: Sub-Investigator

NCT03945279 PI: Ravits, J July 2019 – June 2021
 Biogen
A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BIIB100 administered orally to adults with ALS.
 Role: Sub-Investigator

NCT03626012 PI: Ravits, J July 2019 – November 2021
 Biogen
A study to assess the safety, tolerability, and pharmacokinetics of BIIB078 administered intrathecally to adults with C9ORF72-associated ALS.
 Role: Sub-Investigator

NCT03805750 PI: Wright, BA July 2019 – July 2022
 Tilray/International ET foundation/Center for Medical Cannabis Research
Double-blind, placebo-controlled, crossover study assessing efficacy and tolerability of an oral CBD/THC compound for treatment of Essential Tremor
 Role: Primary Investigator

NCT03741920 PI: Wright, BA July 2019 – April 2023
 Global Kinetics Corporation
Evaluation of the Personal KinetiGraph™ (PKG™) to improve insight into Parkinson's disease status (APPRISE)
 Role: Primary Investigator

NCT03952806 PI: Litvan, I August 2019 – September 2021
BHV3241-301 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR)
 Role: Sub-Investigator

NCT04057794 PI: Litvan, I August 2019 – April 2023
PDGENERation: Mapping the Future of Parkinson's Disease (PDGENE)
 Role: Sub-investigator

NCT04102579 PI: Corey-Bloom, J February 2020 - present
 Neurocrine Biosciences
Efficacy, safety, and tolerability of Valbenazine for the treatment of chorea associated with Huntington disease (KINECT-HD)
 Role: Sub-investigator

NCT04406636 PI: Corey-Bloom, J May 2020 – March 2023
 Triplet Therapeutics Inc.
Natural history study in Huntington disease gene expansion carriers (SHIELD-HD)
 Role: Sub-investigator

Brenton A. Wright, M.D.

NCT04556656 PI: Corey-Bloom, J October 2020 - present
 Prilenia Therapeutics
Pridopidine's outcome on function in Huntington disease (PROOF-HD)
 Role: Sub-investigator

NCT04539041 PI: Litvan, I January 2022 – February 2023
 Novartis
Safety, tolerability, and pharmacokinetics of multiple ascending doses of NIO752 in Progressive Supranuclear Palsy (PSP)
 Role: Sub-investigator

NCT04993768 PI: Wright, BA February 2022 – April 2023
 Transposon Therapeutics
A Phase 2a Study of TPN-101 in patients with Progressive Supranuclear Palsy
 Role: Primary Investigator

BIBLIOGRAPHY

Peer-reviewed Journal Publications

Wright BA, Roberts CS, Seligson D, Malkani AL, McCabe, SJ. Cost of antibiotic beads is justified: A study of open fracture wounds and chronic osteomyelitis. *J Long Term Eff Med Implants*. 2007; 17 (3): 181-185.

Wright BA and Waters CH. Continuous dopaminergic delivery to minimize motor complications in Parkinson's disease. *Expert Rev Neurother*. 2013; 13 (6): 719-729.

Wright BA, Michalec M, and Louis ED. Triggering essential head tremor with sustained phonation: a clinical phenomenon with potential diagnostic value. Study of 102 ET patients with head tremor. *Parkinsonism Relat Disord*. 2014; 20 (2): 230-232.

Sampson JB, Michaeli T, Wright, BA, Goldman JE, Vonsattel JP, Fahn S. Basal ganglia gliosis in a case of rapid onset dystonia-parkinsonism (DYT12) with a novel mutation in ATPase 1A3 (ATP1A3). *Mov Disord Clin Pract*. 2016; 3 (6): 618-620.

Nielsen SS, Warden MN, Camacho-Soto A, Willis AW, Wright BA, and Racette BA. A predictive model to identify Parkinson disease from administrative claims data. *Neurology*. 2017; 89 (14): 1448-1456.

Moreno GM, Gandhi R, Lessig SL, Wright B, Litvan I, Nahab FB. Mortality in patients with Parkinson disease psychosis receiving pimavanserin and quetiapine. *Neurology*. 2018; 91 (17): 797-799. PMID: 30258020
 Bayram E, Litvan I, Wright BA, Grembowski C, Shen Q, Harrington DL. Dopamine effects on memory load and distraction during visuospatial working memory in cognitively normal Parkinson's disease. *Neuropsychol Dev Cogn B Aging Neuropsychol Cogn*. 2020 Oct 6:1-17. doi: 10.1080/13825585.2020.1828804. Epub ahead of print. PMID: 33021874; PMCID: PMC8021591.

Brownstein MJ, Simon NG, Long JD, Yankey J, Maibach HT, Cudkowicz M, Coffey C, Conwit RA, Lungu C, Anderson KE, Hersch SM, Ecklund DJ, Damiano EM, Itzkowitz DE, Lu S, Chase MK, Shefner JM, McGarry A, Thornell B, Gladden C, Costigan M, O'Suilleabhain P, Marshall FJ, Chesire AM, Deritis P, Adams JL, Hedera P, Lowen K, Rosas HD, Hiller AL, Quinn J, Keith K, Duker AP, Gruenwald C, Molloy A, Jacob C, Factor S, Sperin E, Bega D, Brown ZR, Seeberger LC, Sung VW, Bengel M, Kostyk SK, Daley AM, Perlman S, Suski V, Conlon P, Barrett MJ, Lowenhaupt S, Quigg M, Perlmutter JS, Wright BA, Most E, Schwartz GJ, Lamb J, Chuang RS, Singer C, Marder K, Moran JA, Singleton JR, Zorn M, Wall PV, Dubinsky RM, Gray C, Drazinic C. Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial. *J Clin Med*. 2020 Nov 16;9(11):3682. doi: 10.3390/jcm9113682. PMID: 33207828; PMCID: PMC7696926.

Corey-Bloom J, Williams ME, Beltran-Najera I, Mustafa AI, Snell CM, Castleton J, Smith H, Wright B, Gilbert PE. Central Cognitive Processing Speed Is an Early Marker of Huntington's Disease Onset. *Mov Disord Clin Pract*. 2020 Dec 28;8(1):100-105. doi: 10.1002/mdc3.13121. PMID: 33426164; PMCID: PMC7781078.

Brenton A. Wright, M.D.

Merola A, Kobayashi N, Romagnolo A, Wright BA, Artusi CA, Imbalzano G, Litvan I, Van Laar AD, Bankiewicz K. Gene Therapy in Movement Disorders: A Systematic Review of Ongoing and Completed Clinical Trials. *Front Neurol*. 2021 Apr 6; 12:648532. doi: 10.3389/fneur.2021.648532. PMID: 33889127; PMCID: PMC8056023.

Sato C, Mallipeddi N, Ghoshal N, Wright BA, Day GS, Davis AA, Kim AH, Zipfel G, Bateman RJ, Gabelle A, Barthélemy NR. MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology. *Ann Clin Transl Neurol*. 2021 Sep;8(9):1817-1830. doi: 10.1002/acn3.51435. Epub 2021 Aug 2. PMID: 34342183; PMCID: PMC8419397.

Coughlin DG, Dryden I, Goodwill VS, Pizzo DP, Wright B, Lessig S, Galasko D, MacKenzie IR, Hiniker A. Long-standing multiple system atrophy-Parkinsonism with limbic and FTL D-type α -synuclein pathology. *Neuropathol Appl Neurobiol*. 2022 Apr;48(3): e12783. doi: 10.1111/nan.12783. Epub 2021 Dec 13. PMID: 34847258.

Horie K, Barthélemy NR, Spina S, VandeVrede L, He Y, Paterson RW, Rohrer JD, Wright BA, Day GS, Davis AA, Karch CM, Seeley WW, Perrin RJ, Ghoshal N, Gabelle A, Boxer AL, Bateman RJ, Sato C. CSF tau microtubule-binding region identifies pathological changes in primary tauopathies. *Nat Med* 2022 Nov 24; doi: 10.1038/s41591-022-02075-9. [Epub ahead of print] PMID: 36424467.

Hughes SB, Churchill E, Smirnova A, Hall A, Culbert B, Snell C, Wright BA, Gilbert PE, Corey-Bloom J. Anosognosia in HD: Comparison of self-report and caregiver ratings with objective performance measures. *Parkinsonism Relat Disord*. 2022 Dec 29; 107:105272. doi: 10.1016/j.parkreldis.2022.105272. Epub ahead of print. PMID: 36610230.

Longardner K, Wright BA, Alakkas A, You H, Xu R, et al. (2023) Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. *PLOS ONE* 18(1): e0278262. <https://doi.org/10.1371/journal.pone.0278262>

Complete list of published work in:

<https://www.ncbi.nlm.nih.gov/myncbi/1rUAWRuMk5xQn/bibliography/public/>

Scientific Abstracts

Wright BA, Lewis L, Noble J, Vonsattel JP, Khandji A, Sommerville RB, Wright C. Case Series: Eosinophilic vasculitis isolated to the central nervous system. Presented March 19, 2013 at the American Academy of Neurology annual meeting.

Wright BA, Sampson JB, Vonsattel JP, Goldman JE, Fahn S. Unique presentation of primary generalized dystonia with novel findings on post-mortem brain pathology. Presented June 12, 2014 at the International Congress of Parkinson's Disease and Movement Disorders. Travel Grant Recipient

Sampson JB, Michaeli T, Wright BA, Vonsattel JP, Fahn S, Goldman JE. Unique astrocyte pathology in a case of Rapid Onset Dystonia-Parkinsonism (DYT12) with novel mutation in ATP1A3. Presented April 21, 2015, American Academy of Neurology annual meeting.

Corey-Bloom J, Wong C, Aboufadel S, Snell C, Castleton J, Smith H, Wright BA, Gilbert PE. Using the Huntington's disease-Behavioral Questionnaire (HD-BQ) as a screening tool for behavioral disturbances in HD. Presented November 8, 2019, Huntington Study Group Annual Meeting.

Corey-Bloom J, Wong C, Aboufadel S, Snell C, Castleton J, Smith H, Wright BA, Gilbert PE. Using the Huntington's disease-Behavioral Questionnaire (HD-BQ) as a screening tool for behavioral disturbances in HD. Presented April 28, 2020 American Academy of Neurology Annual Meeting.

Corey-Bloom J, Williams ME, Wong C, Aboufadel S, Snell C, Wright BA, Gilbert PE. Central cognitive processing speed is an early marker of Huntington's disease onset. Presented April 28, 2020, American Academy of Neurology Annual Meeting.

Sato C, Horie K, Barthélemy NR, Patterson BW, Gordon BA, Benzinger TL, Mallipeddi N, Sullivan M, Elbert D, Wright BA, Day GS, Davis AA, Paterson RW, Ghoshal N, Bateman RJ. Tau kinetics in Alzheimer disease and primary tauopathies. Presented July 28, 2020 Alzheimer's Association International Conference.

Corey-Bloom J, Hall A, Snell C, Wright BA, Caligiuri M. Can handwriting movement abnormalities serve as an early biomarker of transition to manifest Huntington's disease? Presented September 14, 2020 International Parkinson and Movement Disorder Society Virtual Congress.

Brenton A. Wright, M.D.

Snell C, Smith H, Castleton J, Hall A, Smirnova A, Wright BA, Gilbert PE, Corey-Bloom J. How well does the Composite Unified Huntington's disease Rating Scale (cUHDRS) reflect disease progression in Huntington's disease (HD)? Presented September 14, 2020 International Parkinson and Movement Disorder Society Virtual Congress.

Smith H, Snell C, Castleton J, Castleton J, Hall A, Smirnova A, Wright BA, Gilbert PE, Corey-Bloom J. Does the Composite Unified Huntington's disease Rating Scale (cUHDRS) correlate with disease progression in Huntington's disease (HD)? Presented October 30, 2020 Huntington Study Group Annual Meeting.

Smith H, Snell C, Castleton J, Castleton J, Hall A, Smirnova A, Wright BA, Gilbert PE, Corey-Bloom J. How well does the Composite Unified Huntington's disease Rating Scale (cUHDRS) reflect disease progression in Huntington's disease (HD)? April 12-21, 2021 American Academy of Neurology Annual Meeting.

Sato C, Mallipeddi N, Ghoshal N, Wright BA, Day GS, Davis AA, Kim AH, Zipfel G, Bateman RJ, Gabelle A, Barthélemy NR. CSF Tau phosphorylation occupancy at T217 increases in MAPT R406W mutation carriers in the absence of amyloid pathology. Presented July 2021, Alzheimer's Association International Conference.

McCallum R, Parkman H, Kunkel D, Nguyen L, Wright B, Kalas M, Quesenberry C, Ramamoorthy B, Donders J, Hyde B. Revisiting the risk of Tardive Dyskinesia with metoclopramide use: a real-world data driven epidemiology study of patients from 2011-2021. Presented May 2022, Digestive Disease Week (DDW) National Meeting.

Horie K, Barthélemy NR, Spina S, VandeVrede L, He Y, Paterson RW, Rohrer JD, Wright BA, Day GS, Davis AA, Karch CM, Seeley WW, Perrin RJ, Koppiseti RK, Lago AL, Heuer H, Ghoshal N, Gabelle A, Miller BL, Boxer AL, Bateman RJ, Sato C. CSF tau microtubule binding region identifies pathological changes in primary tauopathies. Presented August 2022, Alzheimer's Association International Conference.

Hughes SB, Smirnova A, Hall A, Snell CM, Wright BA, Gilbert PE, Corey-Bloom J. Anosognosia in HD: Comparison of Self-Report and Caregiver Ratings with Objective Performance Measures. International Parkinson and Movement Disorder Society International Congress, Madrid, Spain, September 2022.

Culbert B, Caligiuri M, Churchill E, Prasad N, Snell C, Hall A, Smirnova A, Wright BA, Corey-Bloom J. Graphomotor Predictors of Motor and Functional Decline in Premanifest Huntington's Disease. Huntington Study Group, Tampa, FL, November 2022.

Hughes SB, Churchill E, Smirnova A, Hall A, Culbert B, Snell C, Hutchings Z, Wright BA, Gilbert PE, Corey-Bloom J. Anosognosia in HD: Comparing Objective Performance with Self-Report and Caregiver Ratings as a Measure of Anosognosia in HD. Huntington Study Group, Tampa, FL, November 2022.

UC San Diego School of Medicine Formal Teaching Roles

MS-2 Small Group Neurological Exam Instruction. January 2022

MS-1 Mind Brain & Behavior Small Group Neurology Case Discussions. January-February 2022 and 2023

Lectures

Movement Disorders Journal Club, Washington University in St. Louis

Neurotrophic Factors for Treatment of Parkinson's disease. March 13, 2014

Faculty and Resident Conference, Dept. of Neurology, Oregon Health & Science University.

Neurotrophic Factors for Treatment of Parkinson's disease. April 17, 2014

Movement Disorders Journal Club, Washington University in St. Louis

Huntington's disease research update. November 20, 2014

Movement Disorders Journal Club, Washington University in St. Louis

Carbidopa Levodopa Enteral Suspension for Parkinson's disease. February 19, 2015

St. Louis APDA Chapter, YOPD Support Group

Carbidopa Levodopa Enteral Suspension for Parkinson's disease. March 17, 2015

Washington University Department of Physical Therapy, Student Curriculum

Overview of Ataxia. November 9, 2015

Huntington Disease Society of America, St. Louis Chapter

Update on Research and Clinical trials. March 19, 2016

Washington University Department of Neurosurgery Resident Curriculum

Cerebellar Physiology and Ataxia Syndromes. March 23, 2016

Brenton A. Wright, M.D.

St. Louis APDA Chapter - Overview and Expert Panel on DBS Surgery vs. Duopa™ for Parkinson disease.
April 3, 2016

Movement Disorders Journal Club, Washington University in St. Louis
Normal Pressure Hydrocephalus - Comprehensive Literature Review. May 19, 2016

Movement Disorders Journal Club, Washington University in St. Louis
Huntington's disease research update. November 17, 2014

Washington University Department of Physical Therapy, Student Curriculum
Overview of Ataxia. November 21, 2016

Huntington Study Group – Website Curriculum for Physician Educational Resource on HD
Creation of online visual content; filmed for video lecture content.
HSG meeting November 2, 2016

Washington University Department of Neurology Grand Rounds
Resident Clinical-Pathologic Conference – Faculty Discussant. May 26, 2017

University of California San Diego Movement Disorders Division Conference
The Braak Hypothesis for Pathological Staging of Parkinson Disease –
A Critical Analysis. June 14, 2017

Washington University Department of Physical Therapy, Student Curriculum Overview of Ataxia. November 6, 2017

UC San Diego Health – Educating the Community – Focus on Health Seminar
Parkinson disease – Exercise as Medicine. January 25, 2018

UC San Diego Health – Educating the Community – Focus on Health Symposium
Parkinson disease – Medical Management of Motor Symptoms. June 2, 2018

University of California San Diego Movement Disorders Division Conference
Video Rounds Case Conference. August 29, 2018

UC San Diego Health – Educating the Community – Focus on Health Symposium
Shaking Out the Subtleties of Tremor – Parkinsonian Tremor. November 1, 2018

University of California San Diego – Department of Internal Medicine
Resident Recruitment Morning Report “Stiff Person Syndrome” Faculty Discussant.
November 15, 2018

Dystonia Support & Advocacy Group of San Diego County
Overview of Dystonia – Clinical Characteristics and Treatments. January 5, 2019

UC San Diego Neurology Resident Curriculum
Cerebellar Physiology and Ataxia Syndromes. January 18, 2019

UC San Diego Health – Educating the Community – Focus on Health Symposium
Newly-FDA Approved Medications for Parkinson disease. March 16, 2019

UC San Diego Neurology Resident and Movement Disorders Fellow Curriculum
Botulinum Toxin for Movement Disorders – Overview & Demonstration.
March 29, 2019

UC San Diego Movement Disorders Fellow Curriculum
Normal Pressure Hydrocephalus - Comprehensive Literature Review. May 3, 2019

UC San Diego Movement Disorders Fellow Curriculum
The Braak Hypothesis for Pathological Staging of Parkinson Disease –
A Critical Analysis. May 3, 2019

UC San Diego Movement Disorders Fellow Curriculum
Botulinum Toxin for Movement Disorders – Overview & Demonstration.
Sept 25, 2019

Parkinson's Foundation: Aware in Care Ambassador Training:
Parkinson's in the Hospital. September 27, 2019

Parkinson's Association of San Diego – Empowerment Symposium for Parkinson's
Overview of Medications for Parkinson's disease. November 15, 2019

Lewy Body and Frontotemporal Dementia, Support and Discussion Group @ Alzheimer's
San Diego. Overview and Q & A on Lewy Body Dementia, Frontotemporal
Dementia, and Multiple System Atrophy. December 4, 2019

University of California San Diego – Department of Internal Medicine
Resident Morning Report “Autoimmune Encephalitis” Faculty Discussant.
January 7, 2020

UC San Diego Movement Disorders Fellow Curriculum
The Braak Hypothesis for Pathological Staging of Parkinson Disease –
A Critical Analysis. March 20, 2020

UC San Diego Movement Disorders Fellow Curriculum
Normal Pressure Hydrocephalus - Comprehensive Literature Review.
March 20, 2020

UC San Diego Movement Disorders Fellow Curriculum

Brenton A. Wright, M.D.

